Floatz logo

azd8931

Advanced Solid Malignancies

AstraZenecaPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

26 Active assets in the Advanced Solid Malignancies cohort.

Asset / SponsorPhaseRating
Durvalumab
AstraZeneca
Phase 3B
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
AstraZeneca
Phase 3B
FULVESTRANT
Carrick Therapeutics Limited
Phase 1/2B
prj1-3024
Zhuhai Yufan Biotechnologies Co., Ltd
Phase 1/2CCC
Encequidar
Hanmi Pharmaceutical Company Limited
Phase 1CCC

View all 50 →

Same molecule, other indications

azd8931 is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →
neoplasmDormant
B
Indicative ·
57 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →